VPT:CC - Ventripoint Diagnostics Exhibiting at the 2022 British Society of Echocardiography
(TheNewswire)
Toronto, Ontario – TheNewswire –October 14, 2022 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to announce that it will be hosting anexhibit at the 2022 British Society of Echocardiography Conference inLondon, England from October 14-15, 2022.
Dr. Gregory Skinner, one of Ventripoint’s clinicaladvisors will be giving a presentation on his experience using the VMSsystem. This will provide excellent exposure for the VMS system andits capabilities for cardiologists and clinicians. This conferencewill further connect Ventripoint to the global echo community anddemonstrate how the VMS+ is a reliable and effective cardiacdiagnostic tool. Ventripoint’s local UK distributor, Cardiologic,will also be participating in the event. This will also providevaluable networking opportunities for Ventripoint’s global partners. This will be the tenth conference the Company has exhibited at thisyear as it continues to the process of introducing a new diagnosticdevice to the cardiology community.
The British Society of Echocardiography (BSE) is aregistered charity that supports clinical echocardiographyprofessionals in order to provide the highest standard of care inechocardiography. BSE was formed in 1990 and has over 4,000 membersworldwide. The conference is the BSE’s 30 th annualconference and has the highest attendance to date. The conference willbe attended both in person and virtually, offering a unique hybridexperience.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2022 TheNewswire - All rights reserved.